BioSpace News Archive

Arthrex to Create 1,000 Jobs With New $74M Facilit

Biotech Bay

Meet the 4 Biotechs That are Disrupting Healthcare

It’s not always easy to see when a company is a “disruptor,” which is to say, that it causes a paradigm shift in how an industry operates.

November 14, 2017

·

3 min read

·

Mark Terry

3 Biotechs That Got Huge Boosts From Spark's FDA P

Pharm Country

3 Biotech Stars Investors Should Load Up On in November

At 14.1%, healthcare is the third largest weighted sector in the S&P 500 index, and with 76 million baby boomers getting older and living longer, owning healthcare stocks in your portfolio makes sense.

November 14, 2017

·

1 min read

Drug Development

Amgen’s Repatha Reduces Cardiovascular Events in Patients with a History of Heart Attacks

New data shows Repatha hit its primary endpoint and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.

November 14, 2017

·

4 min read

·

Alex Keown

Business

Deciphera Pharmaceuticals Announces Third Quarter 2017 Financial Results and Corporate Highlights

As of September 30, 2017, Deciphera Pharmaceuticals reported cash and cash equivalents of $82.1 million.

November 14, 2017

·

10 min read

American Academy of Ophthalmology Release: Stem Cell Therapy Shows Promise for Common Cause of Blindness

Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

November 14, 2017

·

4 min read

Business

PositiveID Reports Third Quarter 2017 Results; Revenues increase 38% Year over Year

Company also improves operating results, reducing operating loss 74% for the third quarter of 2017 from the third quarter of 2016.

November 14, 2017

·

7 min read

Biotech Beach

Clarify Medical Announces National Launch of Home Light Therapy System for Psoriasis

Clarify Medical announced today that its FDA-cleared home-based treatment technology for psoriasis and vitiligo is now rolling out for national distribution.

November 14, 2017

·

2 min read

Drug Development

Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform

The AWE Program is designed to provide biopharmaceutical companies with access to the Company’s proprietary AWE technology platform in order to allow development of actinium-225 enabled conjugates wherein targeting agents are labeled with the alpha particle emitting radioisotope, actinium-225.

November 14, 2017

·

8 min read

TESARO Announces U.S. FDA Approval of VARUBI IV fo

FDA

Roche Wins FDA Nod for the VENTANA MMR IHC Panel for Patients Diagnosed With Colorectal Cancer

The tests detect certain proteins associated with a DNA repair mechanism called MMR, and aid in differentiating between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer.

November 14, 2017

·

5 min read

ProQR Prices Approximately $20M Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

November 14, 2017

·

4 min read